Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649038 | Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg | PHASE1 | COMPLETED | 24 | — | — | Dec 1, 2002 | Dec 1, 2002 | Apr 24, 2024 | 1 | United States |
| NCT00649597 | Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg | PHASE1 | COMPLETED | 56 | — | — | Nov 1, 2002 | Dec 1, 2002 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg |
| 2 | ACTIVE_COMPARATOR | Lotensin HCT® Tablets 20 mg/25 mg |
| Name | Type | Description |
|---|---|---|
| Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
| Lotensin HCT® Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
Inclusion Criteria: * 1\. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum -human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening...